How much revenue did Altimmune generate this year?
Altimmune has achieved a revenue of 5,686.3 USD this year.
Altimmune Revenue 2025
Altimmune Revenue
5,686.3 USD
Ticker
ALT
ISIN
US02155H2004
WKN
A2N5Z6
In 2025, Altimmune's sales reached 5,686.3 USD, a -71.57% difference from the 20,000 USD sales recorded in the previous year.
The Altimmune Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 669.3 | 1,60 |
| 2029e | 438.02 | 2,44 |
| 2028e | 270.81 | 3,95 |
| 2027e | 23.91 | 44,72 |
| 2026e | 28.86 | 37,04 |
| 2025e | 0.01 | 187995,71 |
| 2024 | 0.02 | 53450,00 |
| 2023 | 0.43 | 2509,39 |
| 2022 | -0.07 | -15271,43 |
| 2021 | 4.41 | 242,40 |
| 2020 | 8.19 | 130,53 |
| 2019 | 5.8 | 184,31 |
| 2018 | 10.33 | 103,48 |
| 2017 | 10.74 | 99,53 |
| 2016 | 3.24 | 329,94 |
| 2015 | 10.64 | 100,47 |
| 2014 | 10.19 | 104,91 |
| 2013 | 17.91 | 59,69 |
| 2012 | 25.18 | 42,45 |
| 2011 | 24.27 | 44,05 |
| 2010 | 20.99 | 50,93 |
| 2009 | 27.55 | 38,80 |
| 2008 | 32.91 | 32,48 |
| 2007 | 14.64 | 73,02 |
| 2006 | 1.66 | 643,98 |
| 2005 | 0.59 | 1811,86 |
Altimmune Revenue, EBIT, Net Income US02155H2004 · A2N5Z6
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Altimmune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Altimmune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Altimmune’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Altimmune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Altimmune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Altimmune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Altimmune’s growth potential.
Altimmune Revenue, EBIT and net profit per share
| Date | Altimmune Revenue | Altimmune EBIT | Altimmune Net Income |
|---|---|---|---|
| 2030e | 669.3 M undefined | 818.68 M undefined | 412.35 M undefined |
| 2029e | 438.02 M undefined | 339.03 M undefined | 278.01 M undefined |
| 2028e | 270.81 M undefined | 135.8 M undefined | 211.79 M undefined |
| 2027e | 23.91 M undefined | -151.95 M undefined | -90.67 M undefined |
| 2026e | 28.86 M undefined | -138.39 M undefined | -103.21 M undefined |
| 2025e | 5,686.3 undefined | -111.53 M undefined | -94.49 M undefined |
| 2024 | 20,000 undefined | -103.17 M undefined | -95.06 M undefined |
| 2023 | 426,000 undefined | -83.51 M undefined | -88.45 M undefined |
| 2022 | -70,000 undefined | -87.74 M undefined | -84.71 M undefined |
| 2021 | 4.41 M undefined | -85.54 M undefined | -97.09 M undefined |
| 2020 | 8.19 M undefined | -54.8 M undefined | -49.04 M undefined |
| 2019 | 5.8 M undefined | -20.46 M undefined | -20.97 M undefined |
| 2018 | 10.33 M undefined | -17.89 M undefined | -42.48 M undefined |
| 2017 | 10.74 M undefined | -16.13 M undefined | -51.36 M undefined |
| 2016 | 3.24 M undefined | -11.09 M undefined | -11.46 M undefined |
| 2015 | 10.64 M undefined | -800,000 undefined | -3.44 M undefined |
| 2014 | 10.19 M undefined | -10.19 M undefined | -9.96 M undefined |
| 2013 | 17.91 M undefined | -10.84 M undefined | -11.72 M undefined |
| 2012 | 25.18 M undefined | -6.27 M undefined | -4.92 M undefined |
| 2011 | 24.27 M undefined | -11.73 M undefined | -3.8 M undefined |
| 2010 | 20.99 M undefined | -18.91 M undefined | -34.85 M undefined |
| 2009 | 27.55 M undefined | -25.97 M undefined | -32.28 M undefined |
| 2008 | 32.91 M undefined | -19.11 M undefined | -36.42 M undefined |
| 2007 | 14.64 M undefined | -16.51 M undefined | -17.72 M undefined |
| 2006 | 1.66 M undefined | -14.53 M undefined | -21.72 M undefined |
| 2005 | 590,000 undefined | 330,000 undefined | 280,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 590,000 USD | 330,000 USD | 280,000 USD |
| 2006 | 1.66 M USD | -14.53 M USD | -21.72 M USD |
| 2007 | 14.64 M USD | -16.51 M USD | -17.72 M USD |
| 2008 | 32.91 M USD | -19.11 M USD | -36.42 M USD |
| 2009 | 27.55 M USD | -25.97 M USD | -32.28 M USD |
| 2010 | 20.99 M USD | -18.91 M USD | -34.85 M USD |
| 2011 | 24.27 M USD | -11.73 M USD | -3.8 M USD |
| 2012 | 25.18 M USD | -6.27 M USD | -4.92 M USD |
| 2013 | 17.91 M USD | -10.84 M USD | -11.72 M USD |
| 2014 | 10.19 M USD | -10.19 M USD | -9.96 M USD |
| 2015 | 10.64 M USD | -800,000 USD | -3.44 M USD |
| 2016 | 3.24 M USD | -11.09 M USD | -11.46 M USD |
| 2017 | 10.74 M USD | -16.13 M USD | -51.36 M USD |
| 2018 | 10.33 M USD | -17.89 M USD | -42.48 M USD |
| 2019 | 5.8 M USD | -20.46 M USD | -20.97 M USD |
| 2020 | 8.19 M USD | -54.8 M USD | -49.04 M USD |
| 2021 | 4.41 M USD | -85.54 M USD | -97.09 M USD |
| 2022 | -70,000 USD | -87.74 M USD | -84.71 M USD |
| 2023 | 426,000 USD | -83.51 M USD | -88.45 M USD |
| 2024 | 20,000 USD | -103.17 M USD | -95.06 M USD |
| 2025e | 5,686.3 USD | -111.53 M USD | -94.49 M USD |
| 2026e | 28.86 M USD | -138.39 M USD | -103.21 M USD |
| 2027e | 23.91 M USD | -151.95 M USD | -90.67 M USD |
| 2028e | 270.81 M USD | 135.8 M USD | 211.79 M USD |
| 2029e | 438.02 M USD | 339.03 M USD | 278.01 M USD |
| 2030e | 669.3 M USD | 818.68 M USD | 412.35 M USD |
Altimmune stock margins US02155H2004 · A2N5Z6
The Altimmune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Altimmune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Altimmune.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Altimmune's sales revenue. A higher gross margin percentage indicates that the Altimmune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Altimmune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Altimmune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Altimmune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Altimmune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Altimmune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Altimmune Margin History
| Altimmune Gross margin | Altimmune Profit margin | Altimmune EBIT margin | Altimmune Profit margin |
|---|---|---|---|
| 2030e | 100.47 % | 122.32 % | 61.61 % |
| 2029e | 100.47 % | 77.4 % | 63.47 % |
| 2028e | 100.47 % | 50.15 % | 78.21 % |
| 2027e | 100.47 % | -635.61 % | -379.26 % |
| 2026e | 100.47 % | -479.51 % | -357.63 % |
| 2025e | 100.47 % | -1.96 M % | -1.66 M % |
| 2024 | 100.47 % | -515,860 % | -475,295 % |
| 2023 | 100.47 % | -19,603.29 % | -20,762.21 % |
| 2022 | 100.47 % | 125,342.86 % | 121,014.28 % |
| 2021 | 100.47 % | -1,939.68 % | -2,201.59 % |
| 2020 | 100.47 % | -669.11 % | -598.78 % |
| 2019 | 100.47 % | -352.76 % | -361.55 % |
| 2018 | 100.47 % | -173.18 % | -411.23 % |
| 2017 | 100.47 % | -150.19 % | -478.21 % |
| 2016 | 100.47 % | -342.28 % | -353.7 % |
| 2015 | 100.47 % | -7.52 % | -32.33 % |
| 2014 | 100.47 % | -100 % | -97.74 % |
| 2013 | 100.47 % | -60.52 % | -65.44 % |
| 2012 | 100.47 % | -24.9 % | -19.54 % |
| 2011 | 100.47 % | -48.33 % | -15.66 % |
| 2010 | 100.47 % | -90.09 % | -166.03 % |
| 2009 | 100.47 % | -94.26 % | -117.17 % |
| 2008 | 100.47 % | -58.07 % | -110.67 % |
| 2007 | 100.47 % | -112.77 % | -121.04 % |
| 2006 | 100.47 % | -875.3 % | -1,308.43 % |
| 2005 | 100.47 % | 55.93 % | 47.46 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 100.47 % | 55.93 % | 47.46 % |
| 2006 | 100.47 % | -875.3 % | -1,308.43 % |
| 2007 | 100.47 % | -112.77 % | -121.04 % |
| 2008 | 100.47 % | -58.07 % | -110.67 % |
| 2009 | 100.47 % | -94.26 % | -117.17 % |
| 2010 | 100.47 % | -90.09 % | -166.03 % |
| 2011 | 100.47 % | -48.33 % | -15.66 % |
| 2012 | 100.47 % | -24.9 % | -19.54 % |
| 2013 | 100.47 % | -60.52 % | -65.44 % |
| 2014 | 100.47 % | -100 % | -97.74 % |
| 2015 | 100.47 % | -7.52 % | -32.33 % |
| 2016 | 100.47 % | -342.28 % | -353.7 % |
| 2017 | 100.47 % | -150.19 % | -478.21 % |
| 2018 | 100.47 % | -173.18 % | -411.23 % |
| 2019 | 100.47 % | -352.76 % | -361.55 % |
| 2020 | 100.47 % | -669.11 % | -598.78 % |
| 2021 | 100.47 % | -1,939.68 % | -2,201.59 % |
| 2022 | 100.47 % | 125,342.86 % | 121,014.28 % |
| 2023 | 100.47 % | -19,603.29 % | -20,762.21 % |
| 2024 | 100.47 % | -515,860 % | -475,295 % |
| 2025e | 100.47 % | -1.96 M % | -1.66 M % |
| 2026e | 100.47 % | -479.51 % | -357.63 % |
| 2027e | 100.47 % | -635.61 % | -379.26 % |
| 2028e | 100.47 % | 50.15 % | 78.21 % |
| 2029e | 100.47 % | 77.4 % | 63.47 % |
| 2030e | 100.47 % | 122.32 % | 61.61 % |
Altimmune Aktienanalyse
What does Altimmune do?
Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Altimmune's Sales Figures
The sales figures of Altimmune originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Altimmune’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Altimmune's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Altimmune’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Altimmune stock
How much was the turnover of the company Altimmune compared to the previous year?
The revenue of Altimmune has increased by -71.57% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Altimmune?
The revenue of Altimmune is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Altimmune measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Altimmune so important for investors?
The revenue of Altimmune is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Altimmune pay?
Over the past 12 months, Altimmune paid a dividend of 873 USD . This corresponds to a dividend yield of about 21,497.17 %. For the coming 12 months, Altimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Altimmune?
The current dividend yield of Altimmune is 21,497.17 %.
When does Altimmune pay dividends?
Altimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Altimmune?
Altimmune paid dividends every year for the past 0 years.
What is the dividend of Altimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Altimmune located?
Altimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Altimmune from 2/3/2017 amounting to 2.91 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2017.
When did Altimmune pay the last dividend?
The last dividend was paid out on 2/3/2017.
What was the dividend of Altimmune in the year 2024?
In the year 2024, Altimmune distributed 0 USD as dividends.
In which currency does Altimmune pay out the dividend?
The dividends of Altimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Altimmune
Our stock analysis for Altimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
